Joseph Garner of Stanford University, a keynote speaker at PRIM&R’s 2016 Advancing Ethical Research Conference, points out that only a small number of drugs that are in clinical trials make it to the market. Man or Mouse? Why Drug Research has taken the Wrong Turning: A New Scientist article discusses how the ability to have genetically modified lab animals has shifted researchers focus away from human disease. She argues the mechanisms researchers use to return genetic data need to be reviewed by IRBs, and research groups should create informed consent procedures on the return of raw data.
Nelson proposes that an “anticipatory infrastructure” needs to be developed to return raw data to donors. Researchers are hesitant to provide data because it can be misinterpreted as medical care, but this hesitancy hurts volunteer recruitment. Geneticists Should Offer Data to Participants: In an editorial published in the World View column of Nature, Sarah Nelson, a human-genetics researcher, describes her frustration after her request for access to her raw data was denied by a genetics group she donated to.
In response to drug safety concerns, AllTrials is using this new tool to push pharmaceutical companies and others to publish the results of their clinical trials and increase transparency.
Katherine airtable linkedin trial#
What Clinical Trial Results? Now You Can See Who Isn’t Sharing Their Findings: In this STAT Pharmalot article, Ed Silverman discusses a new online tool by AllTrials that shows how many clinical trial sponsors have failed to report results to . Both universities and pharmaceutical companies have not been complying with a federal reporting law. This week’s Research Ethics Roundup examines the new online transparency tool from AllTrials, returning data to participants in genetic research, concerns about overuse of genetically modified animals, and the potential for placebos as treatments for non-urgent pain.